Short answer
ARVINAS, INC. (ARVN) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $250M (up 1014.7% year over year) with net income of $169M.
Q2 2026 key financials · XBRL
- Revenue
- $250M
- +1014.7% YoY · +1500.6% QoQ
- Net income
- $169M
- +376.8% YoY · +394.1% QoQ
- Operating margin
- 65.7%
- EPS (diluted)
- $2.60
- +409.5% YoY · +388.9% QoQ
Source: XBRL data from the ARVINAS, INC. (ARVN) Q2 2026 10-Q on SEC EDGAR. USD.
ARVINAS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue, profitability, cash flow, and margins not provided in supplied MD&A excerpt
- VEPPANU FDA approval in Q2 2026 for ESR1-mutated ER+/HER2- advanced or metastatic breast cancer
- Rigel license generated $70.0M upfront payment, with potential $15.0M additional upfront payment
- ARV-102 PSP Phase 1b trial on clinical hold pending FDA review of requested information
- ARV-806 dose-escalation enrollment completed, with clinical data planned for second half of 2026
Risk Factors
- New AI and machine-learning risk triggered by deployment in PROTAC discovery and preclinical pharmacokinetic prediction
- VEPPANU commercialization dependence shifted to Rigel after May 2026 exclusive global license
- AI compliance exposure increases as EU AI Act becomes fully effective in August 2026
- Collaboration risk heightened by Genentech termination notice requiring agreement termination in August 2026
- Capital-raising risk remains without committed external funding, potentially diluting stockholders or restricting operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARVINAS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.